LEGN · Legend Biotech Corp · Earnings Call Transcripts & Audio
Market Cap
$3.72B
Shares
194.49M
Volume · Sep 30
2.96M
Avg daily vol (3M)
2.32M
Legend Biotech Corp Earnings Call Transcripts
Quarterly earnings calls for Legend Biotech Corp (LEGN), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲158.7%
$93.99M
−$59.79M
'24 Q1
24-03-31
·
$160.21M
−$125.32M
'24 Q3
24-09-30
·
$186.52M
$26.28M
'24 Q4
24-12-31
▲107.5%
$195.00M
−$100.92M
'25 Q1
25-03-31
▲36.8%
$255.10M
−$125.40M
'25 Q2
25-06-30
▲70%
$272.33M
−$39.69M
'25 Q3
25-09-30
▲56.5%
$305.10M
−$54.30M
'26 Q1
26-05-12
LATEST
▲51.9%
$387.50M
$33.20M
'26 Q2
26-08-11
Annual General Meeting
Investor event
2026-09-24
Legend Biotech Corp (LEGN) September 2026 Annual General Meeting
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-15
Legend Biotech Corp (LEGN) September 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-11
Legend Biotech Corp (LEGN) Q2 2026 Earnings Call
Revenue
$387.50M
▲ 51.9% YoY Diluted EPS
$0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Legend Biotech Corp (LEGN) Q1 2026 Earnings Call Transcript
Confident tone
In Vivo cell therapy pipeline
Earlier-line / frontline opportunity
CARVYKTI commercial growth
Revenue
$305.10M
▲ 56.5% YoY Diluted EPS
$-0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q3
2025-09-30
Legend Biotech Corp (LEGN) Q3 2025 Earnings Call Transcript
Confident tone
ASH 2025 presentations
Regulatory and label updates
Manufacturing capacity expansion
Revenue
$272.33M
▲ 70% YoY Diluted EPS
$-0.11
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Legend Biotech Corp (LEGN) Q2 2025 Earnings Call Transcript
Confident tone
CARVYKTI commercial performance
CARTITUDE clinical trials and frontline expansion
FDA REMS removal and label update
Revenue
$255.10M
▲ 36.8% YoY Diluted EPS
$-0.34
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Legend Biotech Corp (LEGN) Q1 2025 Earnings Call Transcript
Confident tone
CARVYKTI commercial performance
Earlier-line adoption and label expansion
Manufacturing capacity and turnaround time
Revenue
$195.00M
▲ 107.5% YoY Diluted EPS
$-0.27
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Legend Biotech Corp (LEGN) Q4 2024 Earnings Call Transcript
Confident tone
CARVYKTI commercial launch and sales growth
Manufacturing and capacity expansion
ALC monitoring and risk mitigation
Revenue
$186.52M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Legend Biotech Corp (LEGN) Q3 2024 Earnings Call Transcript
Confident tone
CARVYKTI commercial sales growth
Overall survival benefit / CARTITUDE-4
Geographic expansion (OUS)
Revenue
$160.21M
Diluted EPS
$-0.34
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Legend Biotech Corp (LEGN) Q1 2024 Earnings Call Transcript
Confident tone
Commercial launch and demand growth
Manufacturing capacity expansion and supply
CARVYKTI regulatory approvals and label expansion
Revenue
$93.99M
▲ 158.7% YoY Diluted EPS
$-0.16
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Legend Biotech Corp (LEGN) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Legend Biotech Corp (LEGN) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Legend Biotech Corp (LEGN) Q2 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Legend Biotech Corp (LEGN) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–14 of 14 earnings calls